Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 2/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | CCNC | P24863 | 1/20 | 0.30 |
| ▸ | CDK8 | P49336 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13034614 | 0.86 | CYP11B1 (0.35) | CYP11B1CYP11B2 | |
| SCHEMBL13030134 | 0.86 | CHRNB2 (0.35) | CHRNB2CHRNA4 | |
| SCHEMBL13100337 | 0.85 | ROCK2 (0.31) | CYP11B1CYP11B2 | |
| SCHEMBL13029000 | 0.82 | CHRNB2 (0.32) | CYP11B1CYP11B2CHRNB2CHRNA4 | |
| SCHEMBL2066788 | 0.80 | AAK1 (0.39) | CYP11B1CYP11B2CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL13030784 | 0.78 | PIK3C3 (0.31) | — | |
| SCHEMBL13100346 | 0.76 | — | — | |
| SCHEMBL13457775 | 0.76 | HCAR2 (0.31) | — | |
| SCHEMBL805363 | 0.73 | — | — | |
| SCHEMBL13100275 | 0.73 | RAF1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100311714-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS | NOVARTIS AG (CH) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311714-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS | PRKCA, ABL1, MYLK2 | CYP11B1 977/4885CYP11B2 1164/4885CHRNB2 4351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.